These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 15217961

  • 1. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
    Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
    [Abstract] [Full Text] [Related]

  • 2. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y.
    Respirology; 2008 Jun 15; 13(4):510-7. PubMed ID: 18494946
    [Abstract] [Full Text] [Related]

  • 3. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.
    Cancer Chemother Pharmacol; 2012 May 15; 69(5):1277-87. PubMed ID: 22302408
    [Abstract] [Full Text] [Related]

  • 4. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
    Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.
    Ann Oncol; 2006 Dec 15; 17(12):1818-25. PubMed ID: 16980606
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Lung Cancer; 2013 Nov 15; 82(2):288-93. PubMed ID: 24045016
    [Abstract] [Full Text] [Related]

  • 6. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer Group.
    Clin Cancer Res; 2004 Feb 15; 10(4):1318-25. PubMed ID: 14977831
    [Abstract] [Full Text] [Related]

  • 7. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, Shim HS, Jeong J, Kim JH, Kim HR, Cho BC.
    Cancer Chemother Pharmacol; 2016 Mar 15; 77(3):539-48. PubMed ID: 26811178
    [Abstract] [Full Text] [Related]

  • 8. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R, Spanish Lung Cancer Group.
    Clin Lung Cancer; 2017 Mar 15; 18(2):178-188.e4. PubMed ID: 27908619
    [Abstract] [Full Text] [Related]

  • 9. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
    Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhang J, Zhou C.
    Med Oncol; 2011 Dec 15; 28(4):1411-7. PubMed ID: 20467918
    [Abstract] [Full Text] [Related]

  • 10. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
    Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, Yan S, Wu N, Zheng Q, Li S, Chen J, Wang J, Feng Y, Wang Y, Pei Y, Fang J, Yang Y.
    World J Surg Oncol; 2013 Apr 26; 11():96. PubMed ID: 23621919
    [Abstract] [Full Text] [Related]

  • 11. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
    Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G.
    J Clin Oncol; 2006 Oct 10; 24(29):4731-7. PubMed ID: 16966686
    [Abstract] [Full Text] [Related]

  • 12. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
    Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.
    J Clin Oncol; 2013 Jul 01; 31(19):2404-12. PubMed ID: 23690416
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
    Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, Wasylecka-Morawiec M, Wojas-Krawczyk K, Kucharczyk T, Homa I, Kozioł P, Ciesielka M, Chudziak D, Milanowski J.
    Oncol Rep; 2013 Nov 01; 30(5):2385-98. PubMed ID: 23982437
    [Abstract] [Full Text] [Related]

  • 14. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
    Li Y, Wang LR, Chen J, Lou Y, Zhang GB.
    Dis Markers; 2014 Nov 01; 2014():960458. PubMed ID: 24591771
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zhao H, Zhang H, Du Y, Gu X.
    Tumour Biol; 2014 Dec 01; 35(12):12679-88. PubMed ID: 25227663
    [Abstract] [Full Text] [Related]

  • 16. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.
    Cancer; 2012 May 01; 118(9):2525-31. PubMed ID: 22028294
    [Abstract] [Full Text] [Related]

  • 17. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
    Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, Kim TM, Heo DS, Lee SH, Moon KC.
    PLoS One; 2015 May 01; 10(7):e0133371. PubMed ID: 26200905
    [Abstract] [Full Text] [Related]

  • 18. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R, Krawczyk P, Homa-Mlak I, Powrózek T, Ciesielka M, Kozioł P, Milanowski J, Małecka-Massalska T.
    Pathol Oncol Res; 2019 Jul 01; 25(3):1035-1045. PubMed ID: 30066234
    [Abstract] [Full Text] [Related]

  • 19. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.
    Cancer Invest; 2010 Dec 01; 28(10):1078-83. PubMed ID: 20504223
    [Abstract] [Full Text] [Related]

  • 20. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P.
    Ann Oncol; 2004 Aug 01; 15(8):1194-203. PubMed ID: 15277258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.